Syntax Bio
Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine
$14.4MSeries A+
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine
Develops ultrasound-mediated nonviral genetic medicines
Develops functional single-cell analysis tools and platforms for life science research